Mckesson Bismuth
Bismuth Subsalicylate
Mckesson Medical-surgical
Human Otc Drug
NDC 68599-4744Mckesson Bismuth also known as Bismuth Subsalicylate is a human otc drug labeled by 'Mckesson Medical-surgical'. National Drug Code (NDC) number for Mckesson Bismuth is 68599-4744. This drug is available in dosage form of Tablet, Chewable. The names of the active, medicinal ingredients in Mckesson Bismuth drug includes Bismuth Subsalicylate - 262 mg/1 . The currest status of Mckesson Bismuth drug is Active.
Drug Information:
| Drug NDC: | 68599-4744 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Mckesson Bismuth |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Bismuth Subsalicylate |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Mckesson Medical-surgical |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Tablet, Chewable |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | BISMUTH SUBSALICYLATE - 262 mg/1
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Mar, 2022 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 25 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part335 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | McKesson Medical-Surgical
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 308761
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| NUI: | M0002611
N0000180183
|
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). |
| UNII: | 62TEY51RR1
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
| Pharmacologic Class EPC: | Bismuth [EPC]
|
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. |
| Pharmacologic Class CS: | Bismuth [CS]
|
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 68599-4744-7 | 100 PACKET in 1 BOX (68599-4744-7) / 2 TABLET, CHEWABLE in 1 PACKET | 01 Mar, 2022 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose antidiarrheal/antacid
Product Elements:
Mckesson bismuth bismuth subsalicylate dextrates magnesium stearate bismuth subsalicylate salicylic acid bismuth cation silicon dioxide maltodextrin acacia aspartame calcium carbonate cellulose, microcrystalline d&c red no. 27 rh;046
Indications and Usage:
Uses relieves traveler's diarrhea diarrhea upset stomach reliever due to overindulgence in food and drink, including: ⢠heartburn ⢠indigestion ⢠nausea ⢠gas ⢠belching ⢠fullness
Warnings:
Warnings reye's syndrome: children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. when using this product, if changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of reye's syndrome a rare but serious illness. allergy alert: contains salicylate. do not take if you are: allergic to salicylates (including aspirin) taking other salicylate products
Do Not Use:
Warnings reye's syndrome: children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. when using this product, if changes in behavior with nausea and vomiting occur, consult a doctor because these symptoms could be an early sign of reye's syndrome a rare but serious illness. allergy alert: contains salicylate. do not take if you are: allergic to salicylates (including aspirin) taking other salicylate products
When Using:
When using this product a temporary and harmless darkening of the tongue and/or stool may occur.
Dosage and Administration:
Directions chew or dissolve in mouth drink plenty of clear fluids to help prevent dehydration, which may accompany diarrhea adults and children: (12 years and over) chew 2 tablets every 1/2 to 1 hour as needed do not exceed 16 tablets in 24 hours use until diarrhea stops but not more than 2 days children under 12 years: ask a doctor
Stop Use:
Stop use and ask a doctor if symptoms get worse or lasts more than 2 days ringing in the ears or loss of hearing occurs diarrhea lasts more than 2 days
Package Label Principal Display Panel:
Ndc 68599-4744-7 mckesson bismuth tablets 262 mg bismuth suybsalicylate 2 per pack | 100 packs per box mfr # 82473 220r bismuth
Further Questions:
Questions or comments? 1-800-777-4908